Skip to main content

Corixa

(CRXA)

got some good news Tuesday evening on its experimental cancer drug Bexxar: A recommendation for approval from an advisory panel to the Food and Drug Administration.

Corixa is seeking Bexxar's approval as a new treatment for patients with advanced cases of non-Hodgkin's lymphoma. The drug, if approved, would compete directly against Zevalin, a similar drug marketed by

Idec Pharmaceuticals

TheStreet Recommends

(IDPH)

.

At a meeting today of the Oncologic Drugs Advisory Committee, panel members agreed that Bexxar is an effective treatment. The committee's positive recommendation will be passed onto the full FDA, which should complete its review in early May.

Bexxar, like Zevalin, is a new type of cancer fighter -- a monoclonal antibody with an extra kick of radiation attached, which increases its tumor-killing power.

Corixa shares were up 4% to $7.25 before being halted at before the 12:30 p.m. EST start of the panel meeting.